In conclusion, to the best of our knowledge, this is the first study demonstrating that a single intranasal application of the CRHR2 agonist Ucn3 has the potential to prevent the development of anxiety-like behaviors in an SPS animal model of PTSD. Here, CRHR2 is linked to post-traumatic stress disorder.